Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Husam M. Salah; Subhi J. Al'Aref; Muhammad Shahzeb Khan; Malek Al-Hawwas; Srikanth Vallurupalli; Jawahar L. Mehta; J. Paul Mounsey; Stephen J. Greene; Darren K. McGuire; Renato D. Lopes; Marat Fudim

doi:10.1016/j.ahj.2020.12.007

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Husam M. Salah, Subhi J. Al'Aref, Muhammad Shahzeb Khan, Malek Al-Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, J. Paul Mounsey, Stephen J. Greene, Darren K. McGuire, Renato D. Lopes, Marat Fudim

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.

Original language	English (US)
Pages (from-to)	86-91
Number of pages	6
Journal	American heart journal
Volume	233
DOIs	https://doi.org/10.1016/j.ahj.2020.12.007
State	Published - Mar 2021

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ahj.2020.12.007

Cite this

Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lopes, R. D., & Fudim, M. (2021). Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. American heart journal, 233, 86-91. https://doi.org/10.1016/j.ahj.2020.12.007

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes : A meta-analysis update. / Salah, Husam M.; Al'Aref, Subhi J.; Khan, Muhammad Shahzeb; Al-Hawwas, Malek; Vallurupalli, Srikanth; Mehta, Jawahar L.; Mounsey, J. Paul; Greene, Stephen J.; McGuire, Darren K.; Lopes, Renato D.; Fudim, Marat.

In: American heart journal, Vol. 233, 03.2021, p. 86-91.

Research output: Contribution to journal › Letter › peer-review

Salah, HM, Al'Aref, SJ, Khan, MS, Al-Hawwas, M, Vallurupalli, S, Mehta, JL, Mounsey, JP, Greene, SJ, McGuire, DK, Lopes, RD & Fudim, M 2021, 'Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update', American heart journal, vol. 233, pp. 86-91. https://doi.org/10.1016/j.ahj.2020.12.007

Salah, Husam M. ; Al'Aref, Subhi J. ; Khan, Muhammad Shahzeb ; Al-Hawwas, Malek ; Vallurupalli, Srikanth ; Mehta, Jawahar L. ; Mounsey, J. Paul ; Greene, Stephen J. ; McGuire, Darren K. ; Lopes, Renato D. ; Fudim, Marat. / Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes : A meta-analysis update. In: American heart journal. 2021 ; Vol. 233. pp. 86-91.

@article{354c9c71b611487faf4774549d7000de,

title = "Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update",

abstract = "In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.",

author = "Salah, {Husam M.} and Al'Aref, {Subhi J.} and Khan, {Muhammad Shahzeb} and Malek Al-Hawwas and Srikanth Vallurupalli and Mehta, {Jawahar L.} and Mounsey, {J. Paul} and Greene, {Stephen J.} and McGuire, {Darren K.} and Lopes, {Renato D.} and Marat Fudim",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = mar,

doi = "10.1016/j.ahj.2020.12.007",

language = "English (US)",

volume = "233",

pages = "86--91",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes

T2 - A meta-analysis update

AU - Salah, Husam M.

AU - Al'Aref, Subhi J.

AU - Khan, Muhammad Shahzeb

AU - Al-Hawwas, Malek

AU - Vallurupalli, Srikanth

AU - Mehta, Jawahar L.

AU - Mounsey, J. Paul

AU - Greene, Stephen J.

AU - McGuire, Darren K.

AU - Lopes, Renato D.

AU - Fudim, Marat

PY - 2021/3

Y1 - 2021/3

N2 - In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.

AB - In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, and Embase databases for randomized clinical trials comparing cardiovascular and kidney outcomes between SGLT2 and dual SGLT1/2 inhibitors and placebo. Nine randomized clinical trials with a total of 60,914 patients with type 2 diabetes were included. In patients with type 2 diabetes, the use of SGLT2 and dual SGLT1/2 inhibitors improves the cardiovascular and kidney outcome.

UR - http://www.scopus.com/inward/record.url?scp=85099472749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099472749&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2020.12.007

DO - 10.1016/j.ahj.2020.12.007

M3 - Letter

C2 - 33385359

AN - SCOPUS:85099472749

VL - 233

SP - 86

EP - 91

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this